UK-based CRO launches new kinase compound profiling services
Aurelia Bioscience is a contract research organization (CRO) specializing in customized bioassay development, pharmacological profiling, and compound screening.
Aurelia Bioscience Chief Scientific Officer Gary Allenby said the BioCity, Nottingham-based firm is the only CRO in the UK to use Promega’s NanoBRET technology for kinase compound profiling.
Headquartered in Madison, WI, US, Promega’s NanoBRET technology enables reproducible detection of protein interactions in the natural cellular environment, according to the company, which provides products across the fields of genomics, protein analysis and expression, cellular analysis, drug discovery, and genetic identity.
Although recently launched, Allenby said the company has already started receiving several inquiries for the new service, "which proves that there is a high demand.”
“Using Promega’s NanoBRET technology, Aurelia Bioscience has implemented intracellular kinase assays designed to study the interaction of compounds on kinase targets in intact living cells,” Allenby added.
“This technique is compatible with analysis under equilibrium conditions, suitable for a wide range of throughput requirements and a good predictor of cellular potency.”
Allenby said the company hopes to contribute to several kinase drug discovery programs in the next few months.
